Teams led by researchers at George Mason University have published a pair of studies exploring protein signaling in breast and colon cancer that could offer new insights into treatments for the diseases.

Using reverse-phase protein microarrays, the scientists measured HER2 signaling pathways in samples from 415 breast cancer patients and, in a separate effort, profiled protein pathway activation in 34 matched primary colorectal cancers and synchronous hepatic metastasis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.